V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 240008875 | 240005416 | 1.67 | 89.9 | Disease modification (D) | 2016-07-17 | 2016-08-16 | FCR Oral - Cycle 1 | 02 | N | 240028072 | BRENTUXIMAB |
| 240008876 | 240010972 | 1.55 | 75.3 | Curative (C) | 2017-01-06 | 2017-01-06 | Irinotecan + Modified De Gramont | N | N | 240028095 | CISPLATIN + ETOPOSIDE |
| 240008877 | 240010972 | 1.75 | 74 | Adjuvant (A) | 2015-11-21 | 2015-11-23 | CVP | N | N | 240028095 | FCR |
| 240008878 | 240005417 | null | 52.6 | Curative (C) | 2016-03-30 | 2016-04-05 | CYCLOPHOSPHAMIDE + DOCETAXEL + EPIRUBICIN | null | null | 240028501 | R CODOX M |
| 240008879 | 240010973 | 1.69 | 55.9 | Curative (C) | 2019-01-15 | 2019-01-23 | ABVD | null | N | 240028636 | GEMCITABINE |
| 240008880 | 240010973 | 1.77 | 121 | null | 2015-12-19 | 2015-12-20 | CNS Low Grade Glioma Vinblastine | 2 | N | 240028636 | BORTEZOMIB |
| 240008881 | 240005418 | 1.73 | 106 | Disease modification (D) | 2016-07-17 | 2016-08-06 | GEMCITABINE | 2 | N | 240028677 | ESHAP |
| 240008882 | 240005418 | 1.76 | 72 | Adjuvant (A) | 2015-10-04 | 2016-08-13 | Imatinib 400mg | N | N | 240028677 | ICE-R |
| 240008883 | 240005418 | 1.77 | 82 | Curative (C) | 2018-09-04 | 2018-09-30 | Brentuximab Vedotin | N | N | 240028677 | ALEMTUZUMAB |
| 240008884 | 240005419 | 1.81 | 50 | Curative (C) | 2014-11-13 | 2014-11-16 | Cytarabine low (10to20mg/m2) IV/SC | 2 | N | 240028966 | CYCLO + ETOPOSIDE + VINCRISTINE |
| 240008885 | 240005419 | null | 63.5 | null | 2017-12-13 | 2017-12-22 | DOXORUBICIN | null | null | 240028966 | CYCLOPHOSPHAMIDE + GEMCITABINE + RITUXIMAB + VINCRISTINE |
| 240008886 | 240005419 | 1.61 | 47.9 | null | 2015-07-20 | 2015-07-21 | Cytarabine low (10to20mg/m2) IV/SC | N | N | 240028966 | CARBOPLATIN + RT |
| 240008887 | 240005419 | 1.64 | 73.5 | Palliative (P) | 2017-12-11 | 2017-12-14 | Venetoclax | null | N | 240028966 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 240008888 | 240005420 | 1.56 | 59.6 | null | 2015-12-09 | 2015-12-09 | BEVACIZUMAB + CISPLATIN + PACLITAXEL | 01 | N | 240029117 | FIGARO TRIAL |
| 240008889 | 240005421 | 1.79 | 70.4 | Palliative (P) | 2017-05-06 | 2017-05-10 | Bortezomib + CYCLOPHOSPHAMIDE | 2 | N | 240029174 | CISPLATIN + TOPOTECAN |
| 240008890 | 240005422 | 1.65 | 77.2 | null | 2016-09-10 | 2016-10-02 | VEDex | null | N | 240029335 | BEVACIZUMAB + CISPLATIN + PACLITAXEL |
| 240008891 | 240005422 | 1.64 | 82.5 | Curative (C) | 2015-12-31 | 2016-01-16 | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE | N | N | 240029335 | CYCLO + RITUXIMAB + VINCRISTINE |
| 240008892 | 240005422 | 1.56 | 0 | Curative (C) | null | 2017-07-21 | Cisplatin + Topotecan | N | N | 240029335 | PACLITAXEL |
| 240008893 | 240005422 | 1.78 | 77 | Palliative (P) | 2014-06-29 | 2014-06-29 | PMitCEBO-R | N | N | 240029335 | PEMBROLIZUMAB |
| 240008894 | 240005422 | 1.91 | 83 | Curative (C) | 2015-09-05 | 2015-09-06 | CYCLOPHOSPHAMIDE + RITUXIMAB | 02 | N | 240029335 | IBRUTINIB |
| 240008895 | 240005423 | null | 70 | Curative (C) | 2015-11-25 | 2015-11-25 | ECX | Y | N | 240029679 | CISPLATIN + FLUOROURACIL |
| 240008896 | 240005423 | 1.52 | 54.75 | Curative (C) | null | 2017-05-12 | DHAP | N | N | 240029679 | CVP R + GEMCITABINE |
| 240008897 | 240005423 | null | 57 | null | 2013-09-28 | 2013-10-02 | TOPOTECAN | N | null | 240029679 | CARBOPLATIN + RT |
| 240008898 | 240005423 | 1.78 | null | Curative (C) | 2017-07-06 | 2017-07-26 | Cytarabine HD + Methotrexate HD | 02 | null | 240029679 | ABVD |
| 240008899 | 240005424 | 1.62 | 0 | Palliative (P) | 2017-07-15 | 2017-07-18 | Cisplatin + Doxorubicin | 01 | N | 240029940 | AML19 TRIAL |
| 240008900 | 240005425 | 1.77 | 73.3 | Palliative (P) | 2016-09-18 | 2016-09-18 | GemCarbo Days 1+8 | 2 | Y | 240029942 | CYCLO + ETOPOSIDE + VINCRISTINE |
| 240008901 | 240005425 | 1.76 | 50 | Palliative (P) | 2015-12-02 | 2015-12-09 | PMitCEBO-R | N | N | 240029942 | R-EPOCH |
| 240008902 | 240005426 | 1.61 | 84 | Curative (C) | 2015-02-03 | 2015-02-23 | Cisplatin + Paclitaxel | 02 | N | 240030078 | FLAG + IDARUBICIN |
| 240008903 | 240005426 | 1.52 | null | Curative (C) | 2016-06-21 | 2016-06-23 | MITOMYCIN | 2 | null | 240030078 | TRASTUZUMAB EMTANSINE |
| 240008904 | 240005427 | 1.64 | 89.7 | Curative (C) | null | 2018-08-30 | IDARUBICIN + MERCAPTOPURINE + METHOTREXATE + VINCRISTINE | N | N | 240030256 | GEMCITABINE |
| 240008905 | 240010980 | 1.64 | 88.4 | Curative (C) | null | 2014-01-17 | FLUDARABINE | N | Y | 240030314 | CVP |
| 240008906 | 240013665 | 1.61 | 67.1 | Disease modification (D) | null | 2017-06-21 | Capecitabine | N | N | 240030380 | CVP |
| 240008907 | 240005428 | 1.67 | 78.6 | Palliative (P) | 2015-10-29 | 2015-12-13 | CISPLATIN + FLUOROURACIL + RT | 02 | null | 240030463 | ICON TRIAL |
| 240008908 | 240005428 | 0 | 49 | Curative (C) | 2016-11-26 | 2016-12-01 | CTD Attenuated (Thalidomide 50mg) | N | N | 240030463 | RUXOLITINIB |
| 240008909 | 240005429 | 1.63 | 67.4 | Curative (C) | 2018-10-02 | 2018-10-08 | PACLITAXEL | 2 | N | 240030535 | GDP |
| 240008910 | 240005430 | 1.75 | 80.4 | Palliative (P) | 2017-11-20 | 2017-11-28 | AML16 DA 3+10 | null | N | 240030629 | GEMCARBO |
| 240008911 | 240010982 | 1.81 | 56.3 | Curative (C) | 2016-07-08 | 2016-07-15 | CISPLATIN + GEMCITABINE | N | N | 240030666 | R CODOX-M/ R IVAC |
| 240008912 | 240005431 | 1.64 | 65.4 | Curative (C) | 2016-04-22 | 2016-04-28 | LENALIDOMIDE | 02 | N | 240030733 | CISPLATIN + ETOPOSIDE |
| 240008913 | 240005431 | null | 105 | Palliative (P) | 2013-12-20 | 2013-12-23 | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE | 01 | N | 240030733 | ICE |
| 240008914 | 240005431 | 1.61 | 63.2 | Not known (9) | null | 2016-02-29 | CISPLATIN + FLUOROURACIL + RT | N | N | 240030733 | R-EPOCH |
| 240008915 | 240005431 | 1.8 | null | Not known (9) | 2016-08-28 | 2016-08-28 | Nilotinib | N | N | 240030733 | ABVD |
| 240008916 | 240005432 | 1.61 | 77.5 | Palliative (P) | 2014-04-03 | 2014-04-03 | CODOX M | Y | N | 240031104 | FLAG + IDARUBICIN |
| 240008917 | 240005432 | 1.53 | 81 | Curative (C) | 2018-02-13 | 2018-02-13 | AML 18 TRIAL | N | N | 240031104 | GALLIUM TRIAL |
| 240008918 | 240005433 | 1.65 | null | Curative (C) | 2013-10-29 | 2013-10-29 | Triple Intrathecal | N | N | 240031378 | BEVACIZUMAB |
| 240008919 | 240010985 | 1.59 | null | Adjuvant (A) | 2013-12-05 | 2014-01-08 | FCR | null | N | 240031448 | ICE-R |
| 240008920 | 240010985 | 1.56 | null | Neo-adjuvant (N) | 2017-05-02 | 2017-05-02 | Cisplatin + Topotecan | null | N | 240031448 | FCR |
| 240008921 | 240005434 | 1.67 | null | Palliative (P) | 2016-08-31 | 2016-08-31 | Docetaxel | 2 | null | 240031579 | ABVD |
| 240008922 | 240005435 | 1.62 | 82.7 | Disease modification (D) | 2018-06-20 | 2018-06-20 | Carboplatin + Liposomal Doxorubicin | N | N | 240031751 | IPILIMUMAB |
| 240008923 | 240005435 | 1.57 | 76 | Palliative (P) | 2015-11-18 | 2015-11-18 | CVP R + GEMCITABINE | Y | null | 240031751 | CARBOPLATIN + RT |
| 240008924 | 240005436 | 1.62 | 68 | Curative (C) | 2014-11-19 | 2015-04-05 | CYCLO + RITUXIMAB + VINCRISTINE | N | N | 240031958 | CYCLOPHOSPHAMIDE + RITUXIMAB |